Icaritin, a metabolite of Icarrin, Alleviates non-alcoholic fatty liver disease via inhibition of lipogenesis and ER stress.

MLA

Yu, Peng, et al. “Icaritin, a Metabolite of Icarrin, Alleviates Non-Alcoholic Fatty Liver Disease via Inhibition of Lipogenesis and ER Stress.” European Journal of Pharmacology, vol. 937, Dec. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejphar.2022.175378.

APA

Yu, P., Qian, Z., Yang, H., Xu, T., Dai, Y., Song, L., Liang, J., Shi, Y., Zhang, Z., & Li, L. (2022). Icaritin, a metabolite of Icarrin, Alleviates non-alcoholic fatty liver disease via inhibition of lipogenesis and ER stress. European Journal of Pharmacology, 937, N.PAG. https://doi.org/10.1016/j.ejphar.2022.175378

Chicago

Yu, Peng, Zhen Qian, Hongmei Yang, Tianyang Xu, Yulin Dai, Laihui Song, Jinling Liang, Yuying Shi, Zhiguo Zhang, and Lijing Li. 2022. “Icaritin, a Metabolite of Icarrin, Alleviates Non-Alcoholic Fatty Liver Disease via Inhibition of Lipogenesis and ER Stress.” European Journal of Pharmacology 937 (December): N.PAG. doi:10.1016/j.ejphar.2022.175378.